Fosun Pharma

Type: Company
Name: Fosun Pharma
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P.

The previously announced merger agreement was adopted by Chindex's stockholders at a special meeting of stockholders held on September 16Morgan Stanley & Co. LLC served as financial advisor and Hughes Hubbard & Reed LLP served as lead legal advisor to ... [Published Pettinga Financial Advisors - Sep 30 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 2 reports

Fosun Pharma issues Rmb1bn short-term commercial papers

26/09/2014 16:54 [ET Net News Agency, 26 September 2014] Shanghai Fosun Pharmaceutical (02196) said itissued today the first tranche of its short-term commercial papers for 2014 totaling Rmb1billion with a maturity period of 365 days at an interest rate ... [Published etnet.com.hk - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 2 reports

Fosun Pharma Plans Open Platforms For Its Hospitals

Article # 28140924010Posted: Sep. 25, 2014 5:20 AM GMTExecutive SummaryThe chairman of Fosun Pharma mentioned at a broker’s conference that the firm will turn all of its hospitals into open platforms, and set up specialized departments in collaboration ... [Published Health News Daily - Sep 25 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Asia On The Move: Takeda Reorganizes Management Under Weber’s Leadership

Related Biotechnology, Pharmaceutical and Healthcare NewsTakeda has issued continues globalizing its senior management team with a new Global Quality Officer, people news also come from Mitsubishi Tanabe and Fosun Pharma.Original Article: NEXT ARTICLE ... [Published BioPortfolio - Sep 17 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Sinopec plans 300 convenience stores with Taiwan's Ruentex -paper

SHANGHAI, Sept 12 (Reuters) - Sinopec Corp is planning to jointly operate 300 of its convenience stores with Taiwan's Ruentex Group - a move that is likely to enhance the appeal of its massive fuel retail unit in which it is planning to offload a minority ... [Published Reuters India - Sep 12 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Week In Review: DXY Receives $70 Million Investment From Tencent

Deals and FinancingsDXY Group, China's largest healthcare portal, received a $70 million investment from Tencent Holdings (HK: 00700, OTCPK:TCEHY ) in return for an unspecified minority stake in DXY. Tencent is a China internet and mobile phone services ... [Published Seeking Alpha - Sep 08 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Global Market Share is Expanding for U.S.-Based Firms

U.S.-based multinational firms are thriving in a growing global marketArchitects based in the United States are expanding their professional services around the world. DesignIntelligence research projects year-end 2014 billings for services outside the ... [Published Design Intelligence - Sep 04 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 2 reports

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

CleveXel Pharma today announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products.Guilin Pharmaceutical, a member of Fosun Pharma, ... [Published News-Medical.Net - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Nature's Sunshine Closes Venture with China Company

ArticlePress Release September 2, 2014Lehi – Nature's Sunshine Products, Inc. has closed its previously announced China joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and private placement transaction of 2.854 million shares of common ... [Published Utah Business Magazine - Sep 02 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Nature's Sunshine Announces Closing of Private Placement and Joint Venture Agreement With Fosun Pharma

Closed $46.2 million private placement transaction to fund China market entryFosun Pharma acquired 15% stake in Nature's SunshineDeclared $1.50 per share special cash dividendAppointed Dongjiu Li, Senior Vice President of Fosun Pharma, to Nature's Sunshine's ... [Published Industrial Info Financials - Aug 27 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 2 reports

Fosun Pharma (02196) 1H NP RMB1B, down 5%; no div

AM (Infocast News) Results of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) for the first 6 months ended 30 June 2014:Net profit: RMB1.002B, down 4.85% YoYBasic EPS: RMB0.44Dividend proposed ... [Published CCB International - Aug 27 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 2 reports

Fosun Pharma, TPG agree to buy Chindex

Reuters – Chinese drugmaker Shanghai Fosun Pharmaceutical Group Co Ltd and private equity firm TPG Capital agreed to buy China-focused Chindex International Inc in a beefed-up $461 million deal after trumping a rival bid. The U.S.-listed healthcare ... [Published PE Hub Blog - Apr 22 2014]

Quotes

"Our strategic alliance with Fosun Pharma is the first of its kind between a U S company and a Chinese company for direct selling products in China" said Gregory L Probert, chairman and CEO of NatureNature s Sunshine Products
...company for direct selling products in China," commented Gregory L Probert, Chairman and Chief Executive Officer of Nature's Sunshine Products. "Our entry into China marks the beginning of a valuable long-term partnership with Fosun Pharma, as well as a significant step forward as a global organization. As part of our go-to-market strategy, we are focused on completing the regulatory approvals process, establishing the necessary legal entities, recruiting key staff, and moving forward with products to market through a multi-brand, multi-channel approach. We look forward to working with Fosun Pharma to capture the vast opportunity ahead."
NEXT ARTICLE More From BioPortfolio on "Week in Review: Luye Pharma to Raise $764 Million in Hong Kong IPO"
"We rate NATURES SUNSHINE PRODS INC (NATR) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow."

More Content

All (39) | News (28) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Chindex Completes Go-Private Transaction With H... [Published Pettinga Financial Advisors - Sep 30 2014]
Fosun Pharma issues Rmb1bn short-term commercia... [Published etnet.com.hk - Sep 26 2014]
Fosun Pharma (02196) issues RMB1B commercial pa... [Published CCB International - Sep 26 2014]
Fosun Pharma Plans Open Platforms For Its Hospi... [Published Health News Daily - Sep 25 2014]
Fosun Pharma Plans Open Platforms For Its Hospi... [Published BioPortfolio - Sep 25 2014]
China bond market calendar-Sept. 23 [Published Individual.com - Sep 23 2014]
Asia On The Move: Takeda Reorganizes Management... [Published BioPortfolio - Sep 17 2014]
Sinopec plans 300 convenience stores with Taiwa... [Published Reuters India - Sep 12 2014]
CleveXel Pharma partners with Guilin Pharmaceut... [Published European Pharmaceutical Manufacturer - Sep 11 2014]
Healthcare Industry Consolidation: The Rise Of ... [Published Seeking Alpha - Sep 10 2014]
Week In Review: DXY Receives $70 Million Invest... [Published Seeking Alpha - Sep 08 2014]
Sirona Biochem Announces Positive Results In PK... [Published BioSpace - Sep 04 2014]
Global Market Share is Expanding for U.S.-Based... [Published Design Intelligence - Sep 04 2014]
CleveXel Pharma, Guilin Pharmaceutical partner ... [Published News-Medical.Net - Sep 03 2014]
CleveXel Pharma Partners With To Develop Two Ne... [Published BioSpace - Sep 02 2014]
Nature's Sunshine Closes Venture with China Com... [Published Utah Business Magazine - Sep 02 2014]
Nature's Sunshine Announces Closing of Private ... [Published Industrial Info Financials - Aug 27 2014]
In 2013, Chinese in vitro diagnostics market to... [Published Live-PR.com - Aug 27 2014]
Fosun Pharma (02196) 1H NP RMB1B, down 5%; no div [Published CCB International - Aug 27 2014]
Fosun Pharma (02196) 1H net down 4.9% to Rmb1bn... [Published etnet.com.hk - Aug 27 2014]
China Diagnostic Reagent Industry Report, 2013-... [Published PRWeb - Jul 30 2014]
India Bull Unshaken by Selloff as Modi Budget B... [Published Proactiveinvestors United Kingdom RSS feed - Jul 10 2014]
GoPro shares jump after Nasdaq IPO debut [Published FOX Business - Video - Jun 30 2014]
Week in Review Luye Pharma to Raise $764 Millio... [Published BioPortfolio - Jun 29 2014]
Why Nature's Sunshine Products (NATR) Stock Is ... [Published The Street Latest - Jun 26 2014]
Nature's Sunshine Announces Strategic Alliance ... [Published GlobeNewswire: Advertising News - Jun 26 2014]
Why Iraq is a Nation of 3 Peoples Going Separat... [Published Proactiveinvestors United Kingdom RSS feed - Jun 25 2014]
Week in Review BGI Raises $320 Million for Diag... [Published BioPortfolio - Jun 15 2014]
TB Alliance Grants Fosun Pharma Rights to Devel... [Published PR Newswire: Policy & Public Interest - Apr 23 2014]
Fosun Pharma, TPG agree to buy Chindex [Published PE Hub Blog - Apr 22 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
GoPro shares jump after Nasdaq IPO debut [Published FOX Business - Video - Jun 30 2014]
FBN’s Lauren Simonetti on GoPro’s IPO debut, Nature’s Sunshine’s new strategic alliance with Fosun Pharma and Viggle’s acquisition of Choose Digital. ...
TB Alliance Grants Fosun Pharma Rights to Devel... [Published PR Newswire: Policy & Public Interest - Apr 23 2014]
SEATTLE, April 23, 2014 /PRNewswire-USNewswire/ -- TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, has announced that it is collaborating with, and has ...
Fosun Pharma, TPG agree to buy Chindex [Published PE Hub Blog - Apr 22 2014]
Reuters – Chinese drugmaker Shanghai Fosun Pharmaceutical Group Co Ltd and private equity firm TPG Capital agreed to buy China-focused Chindex International Inc in a beefed-up $461 million deal after trumping a rival bid. The U.S.-listed healthcare ...
Chindex Signs Amended Merger Agreement with TPG... [Published PR Newswire: Financial Services - Apr 21 2014]
BEIJING and BETHESDA, Md., April 21, 2014 /PRNewswire/ -- Chindex International, Inc. (NASDAQ: CHDX) ("Chindex" or the "Company"), an American healthcare company providing services in China through the operations of United Family Healthcare, a network ...
CHINDEX INTERNATIONAL INVESTOR ALERT: Faruqi & ... [Published EON Business - Feb 19 2014]
NEW YORK--(EON: Enhanced Online News)--CHINDEX INTERNATIONAL INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Chindex International (CHDX) Over the Proposed Sale of the Company to TPG and Fosun Pharma ...
1 2

Press Releases

sort by: Date | Relevance
Nature's Sunshine Announces Strategic Alliance ... [Published GlobeNewswire: Advertising News - Jun 26 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.